Skip to main content

Table 5 Studies addressing prevalence and clinical association of aPS/PT antibodies

From: Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers

Reference Studied population N Prevalence of anti-PS/PT Clinical association
Galli et al. [33] aPL-positive subjects 59 90% No association with thrombosis
IgG 75%
IgM 66%
Atsumi et al. [37] Patients with autoimmune diseases 265 IgG: PAPS 19%; SLE APS 63%; SLE-no APS 13% Association with APS
IgM: PAPS 10%; SLE APS 29%; SLE-no APS 4%
Nojima et al. [62] SLE patients 126 38.1% No association with stroke
Bertolaccini et al. [47] SLE patients 212 31% No association with thrombosis
IgG-only 16%
IgM-only 6%
Tsutumi et al. [51] SLE patients 139 21% Association with thrombosis
Nojima et al. [52] SLE patients 175 43.4% Association with thrombosis
Bardin et al. [55] APS patients 62 55% NI
Jakowski [56] APS patients 58 44% No association with pregnancy loss
Women with RPL 66 1%
Atsumi et al. [63] Patients with autoimmune diseases 441 18.3% Association with APS
PAPS 84 39%
SLE-APS 68 47%
SLE-no APS 136 10%
Rheumatoid arthritis 46 0
Sjogren syndrome 36 0
Other 71 4%
Žigon et al. [64] APS patients 100 59% NI
Vlagea et al. [65] PAPS patients 98 51%, IgG 35.7%, IgM 32.6% Association with venous thrombosis and obstetric morbidity
SAPS patients 45 53.3%, IgG 40%, IgM 31.1%
aPL-positive subjects 57 38.6%, IgG 21.1%, IgM 26.3%
Pregnolato et al. [26] APS patients 80 81.3% Association with venous thrombosis (IgG only)
  1. aPL, anti-phospholipid antibody; APS, anti-phospholipid syndrome; aPS, anti-phosphatidylserine antibodies; Ig, immunoglobulin; NI, not investigated; PAPS, primary anti-phospholipid syndrome; PS, phosphatidylserine; PT, prothrombin; RPL, recurrent pregnancy loss; SAPS, secondary anti-phospholipid syndrome; SLE, systemic lupus erythematosus.